NervGen Pharma Corp. (NGEN) Key Metrics
NGEN key metrics, 2017–2025
Fiscal year ended December 31, 2025 · Canadian dollarsNGEN returns How much profit the business earns on the capital it uses.
NGEN financial health Debt, liquidity and how easily interest is covered.
NGEN returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
NGEN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
NGEN key metrics in Canadian dollars
2017–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Returns & profitability | |||||||||
| Return on equity (ROE) | — | — | — | −135.6% | −112.1% | −187.9% | −235.8% | −54.0% | — |
| Return on invested capital (ROIC) | — | — | — | — | — | −842.2% | −878.5% | — | — |
| Return on assets (ROA) | −206.7% | −146.7% | −121.3% | −98.5% | −103.7% | −164.4% | −199.9% | −43.9% | — |
| Return on tangible assets | −193.5% | −126.2% | −176.0% | −88.4% | −73.0% | −180.3% | −156.1% | −53.3% | — |
| Financial health | |||||||||
| Total debt | C$8,369 | C$105,531 | C$197,205 | C$280,961 | — | — | — | — | — |
| Cash & short-term investments | C$22.1M | C$17.4M | C$11.7M | C$22.3M | C$17.1M | C$5.6M | C$4.2M | C$2.5M | — |
| Net debt | −C$22.1M | −C$17.2M | −C$11.5M | −C$22.0M | −C$17.1M | −C$5.6M | −C$4.2M | −C$2.5M | — |
| Debt / equity | 0.00 | 0.04 | — | 0.02 | — | — | — | — | — |
| Debt / assets | 0.00 | 0.01 | 0.01 | 0.01 | — | — | — | — | — |
| Current ratio | 1.16 | 1.12 | 0.83 | 2.27 | 16.16 | 8.21 | 6.77 | 5.68 | — |
| Quick ratio | 1.16 | 1.12 | 0.83 | 2.27 | 16.16 | 8.21 | 6.77 | 5.68 | — |
| Interest coverage | — | — | — | -44.7 | — | — | — | — | — |
| Working capital | C$3.1M | C$2.1M | −C$2.6M | C$12.8M | C$16.5M | C$5.5M | C$5.5M | C$2.1M | — |
| Invested capital | −C$18.6M | −C$14.7M | −C$13.5M | −C$8.6M | −C$111,500 | C$322,383 | C$1.8M | C$39,815 | — |
| Tangible asset value | C$3.1M | C$2.1M | −C$2.5M | C$12.9M | C$16.5M | C$5.5M | C$5.5M | C$2.0M | — |
| Net current asset value | C$3.1M | C$2.1M | −C$2.7M | C$12.6M | C$16.5M | C$5.5M | C$5.5M | C$2.0M | — |
| Capital allocation | |||||||||
| Capex / depreciation | 0.00 | 0.00 | 0.04 | 0.18 | 0.06 | 0.09 | 0.00 | 0.00 | — |
| Efficiency | |||||||||
| Days payables outstanding | — | — | 6,699.1 | 6,404.0 | — | — | — | — | — |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Payables turnover | — | — | 0.05 | 0.06 | — | — | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Average receivables | C$247,923 | C$332,625 | C$138,508 | C$45,638 | C$63,610 | C$94,288 | C$75,800 | C$25,760 | — |
| Average payables | C$4.7M | — | C$2.7M | C$2.0M | — | — | — | — | — |
| Intangibles / total assets | 1.8% | 2.4% | 3.9% | 1.8% | 2.6% | 7.1% | 7.5% | 17.7% | — |
Computed from NGEN's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in Canadian dollars; data from EODHD. Averages use the opening and closing balance of each year.
NGEN valuation and financial ratios
It ended the year with C$0.0 million of debt and C$22.1 million in cash and short-term investments, a net cash position of C$22.1 million.
See the NGEN income statement, the NGEN chart for price history, or the NGEN stock overview for the latest quote and news.
NGEN key metrics FAQ
How much debt does NervGen Pharma have?
NervGen Pharma had total debt of C$0.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is NervGen Pharma's current ratio?
NervGen Pharma's current ratio was 1.16 at the end of fiscal 2025: current assets were 1.16 times current liabilities.